AstraZeneca PLC (AZN.L) Company Profile | Reuters.com
Edition:
United States

Profile: AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,467.00GBp
30 Jun 2016
Change (% chg)

-- (--)
Prev Close
4,467.00p
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,709,865
52-wk High
4,634.00p
52-wk Low
3,680.00p

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Company Address

AstraZeneca PLC

- Legal Department, 2 Kingdom St
LONDON     W2 6BD
P: +4420.73045000
F: +4420.76048151

Company Web Links